Comparative Analysis of National Drug Policies - Second Workshop Geneva, 10-13 June 1996 - EDM Research Series No. 025
(1997; 175 pages) View the PDF document
Table of Contents
View the documentExecutive summary
View the documentI. Introduction
Open this folder and view contentsII. Background on the research project
Open this folder and view contentsIII. Second workshop
Close this folderIV. Preliminary findings
Open this folder and view contents1. The methods: What has been learnt?
Open this folder and view contents2. National drug policies: what has been learnt?
Close this folder3. Cross national analysis: What can be learnt at this stage?
View the document3.1 Relevance of the methods for cross national comparison
View the document3.2 Strengths and weaknesses of NDP from a cross national perspective
View the document3.3 Tentative explanations for cross national variations
View the document4. Broader capacity building
Open this folder and view contentsV. Conclusions of the workshop and follow-up plans
Open this folder and view contentsAnnex 1: Research proposal
View the documentAnnex 2: List of participants
View the documentAnnex 3: Agenda
View the documentAnnex 4: Questionnaire on NDP performance assessment
Open this folder and view contentsAnnex 5: Achievements of the national drug policies in the 12 countries
View the documentAnnex 6: Consolidated tables
View the documentOther documents in the DAP Research Series

3.2 Strengths and weaknesses of NDP from a cross national perspective

A number of the findings which were discussed within each country framework are also valid from a cross national perspective. These include that it is easier to put structures in place than to ensure they function properly; that nearly everywhere availability and affordability are seen as the first objectives to achieve. The participants also felt that for certain components there is a universal agreement of their importance and of the fact that they should be taken care of everywhere in a kind of standardized approach:

• selection of drugs;

• procurement by tender in INN;

• drug pricing policy: governments have a role to play in this area of drug affordability although modalities can be different in different countries;

• continuous education and training is also a universal requirement although it is in general the least tackled of all the components.

In contrast, it seemed difficult to have a standardized pattern for budget allocations and public distribution systems.

It was also acknowledged that although all components are equally important everywhere, countries will develop different priorities based on what they perceived as their main problems. This will very often depend on the history of the pharmaceutical sector and the political and socio-economic characteristics of the country.

Time did not allow a review of the strengths or weaknesses of each country nor an attempt to explain them taking as a comparative tool the experiences of the other countries. It was agreed that this should be included in the next phases of the research.

to previous section
to next section
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: December 6, 2017